Jazz says FDA approves Ziihera combos for first-line HER2+ advanced gastroesophageal cancer
JAZZ•FDA approves Ziihera combinations in first-line HER2+ advanced gastroesophageal cancer
Jazz Pharmaceuticals said the FDA cleared Ziihera with tislelizumab and chemotherapy for first-line HER2+ unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).
